Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera versus high-dose octreotide LAR as first-line treatment for advanced G2/G3 GEP-NET
NL-OMON59575Phase 3Active, not recruiting
- Sponsor
- Advanced Accelerator Applications
- Start
- Jan 2021
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing Lutathera + best supportive care octreotide LAR 30 mg with High-dose octreotide LAR 60 mg (2 arms). Primary endpoint: Progression-free survival. Started Jan 2021; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatateoctreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON59575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59575.